ICER draft: Some Vertex CF drug prices should be halved

The Institute for Clinical and Economic Review said the prices of two of three cystic fibrosis drugs from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) would need to be discounted by about half for the drugs to be cost-effective. The comments came

Read the full 399 word article

User Sign In